Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+

Brain Research

Volumn 941, Issue 1-2, 2002, Pages 72-81

  Barc, Stéphanie ^a   Page, Guylène ^a   Barrier, Laurence ^a,b   Huguet, François ^a   Fauconneau, Bernard ^a,b  

^a UPRES EA 1223   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Antioxidant; DAT; MAO inhibitor; MPP+; Rat; Striatum; Substantia nigra

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA TOCOPHEROL; DOPAMINE TRANSPORTER; PARGYLINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG EFFECT; KINETICS; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ALPHA-TOCOPHEROL; ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MONOAMINE OXIDASE INHIBITORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARGYLINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYNAPTOSOMES; TIME FACTORS;

EID: 0037150780     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02567-2     Document Type: Article

References (58)

1. + induced oxygen radical formation with mitochondrial enzymes
2. Biochemistry of neurotransmitters in Parkinson’s disease
3. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys
4. +): Regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation
5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain
6. Modification of DA transporter function: Effect of oxygen species and dopamine
7. 3H]-GBR 12783 specific binding during the maturation of rat striatum
8. + injection into rat substantia nigra causes secondary glial activation but not cell death in the ipsilateral striatum
9. Suppression of hydroxyl radical formation by MAO inhibitors: A novel possible neuroprotective mechanism in dopaminergic neurotoxicity
10. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
11. Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat
12. Effects of ageing on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat
13. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism
14. Animal models of parkinson’s disease: An empirical comparison with the phenomenology of the disease in man
15. MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease
16. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
17. Cloning pharmacological characterization and chromosomal assignment of the human dopamine transporter
18. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
19. Regional studies of catecholamines in rat brain
20. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: Neuroprotective strategies
21. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: The effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat
22. Loss of dopaminergic neurons in parkinsonism: Possible role of reactive dopamine metabolites
23. +) to rats
24. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations
25. 3H-dopamine into synaptosomes from rat striatum
26. + by dopamine neurones explains selective toxicity
27. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice
28. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
29. + administration
30. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey
31. Pargyline prevents MPTP-induced parkinsonism in primates
32. +)-induced apoptosis independent of MAO-B inhibition
33. Experimental models of Parkinson disease
34. + ATPase in rat striatal synaptosomes
35. The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson’s disease
36. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity
37. +
38. 3H]DA uptake and autoxidation in rat striatal slices
39. Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
40. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse
41. A simplification of the protein assay method of Lowry et al. Which is more generally applicable
42. The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
43. Nigral and striatal comparative study of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: Involvement of dopamine uptake system
44. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine
45. Responsiveness of striatal dopamine release in awake animals after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra
46. + to dopaminergic neurons of the rat substantia nigra
47. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid
48. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium
49. Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: Protection by acetyl-L-carnitine
50. +
51. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
52. Rescue from death but not from functional impairment: Caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals
53. Functional studies on monoaminergic transmitter release in parkinsonism
54. +- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens
55. + in vivo
56. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment
57. Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications